TVTX - Travere Therapeutics Inc. (TVTX) Q1 2024 Earnings Call Transcript
2024-05-06 21:33:08 ET
Start Time: 16:30
End Time: 17:26
Travere Therapeutics, Inc. (TVTX)
Q1 2024 Earnings Conference Call
May 06, 2024, 16:30 PM ET
Company Participants
Eric Dube - CEO
Jula Inrig - Chief Medical Officer
Peter Heerma - Chief Commercial Officer
Chris Cline - CFO
Bill Rote - SVP of Research & Development
Anne Crotteau - IR
Conference Call Participants
Anupam Rama - JPMorgan
Tyler Van Buren - TD Cowan
Joseph Schwartz - Leerink Partners
Carter Gould - Barclays
Jason Zemansky - Bank of America
Maury Raycroft - Jefferies
Yigal Nochomovitz - Citigroup
Vamil Davin - Guggenheim Partners
Alex Thompson - Stifel
Laura Chico - Wedbush Securities
Ed Arce - HC Wainwright & Co
Allison Bratzla - Piper Sandler
Presentation
Operator
Good day and welcome to the Travere Therapeutics First Quarter 2024 Financial Results and Corporate Update Conference Call. Today's call is being recorded.
At this time, I would like to turn the conference call over to the Manager of Investor Relations, Anne Crotteau. Please go ahead, Anne.
Anne Crotteau
Thank you, Rachel. Good afternoon and welcome to Travere Therapeutics first quarter 2024 financial results and corporate update call. Thank you all for joining. Today's call will be led by our President and Chief Executive Officer, Dr. Eric Dubey. Eric will be joined in the prepared remarks by Dr. Jula Inrig, our Chief Medical Officer; Peter Heerma, our Chief Commercial Officer; and Chris Cline, our Chief Financial Officer. Dr. Bill Rote, Senior Vice President of Research & Development will join us for the Q&A session.
Before we begin, I would like to remind everyone that statements made during this call regarding matters that are not historical facts are forward-looking statements within the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of performance. They involve known and unknown risk, uncertainties and assumptions that may cause actual results, performance and achievements to differ materially from those expressed or implied by the statement. Please see the forward-looking statement disclaimer on the company's press release issued earlier today as well as the risk factors section in our Form 10-Q and 10-K files with the SEC. In addition, any forward-looking statements represent our views only as of the date such as statements are made, May 6, 2024, and Travere specifically disclaims any obligation to update such statements to reflect future information, events or circumstances.
With that, let me now turn the call over to Eric. Eric?
Eric Dube
Thank you, Anne, and good afternoon, everyone. This year, our organization is focused on executing on the key priorities that will drive sustainable growth for Travere in 2024 and the years ahead. I am pleased to report that we made significant progress on all fronts. Our commercial launch of FILSPARI in the U.S. is continuing to reach new highs. We successfully achieved multiple regulatory milestones with FILSPARI and the first patients were dosed in the pivotal HARMONY study of pegtibatinase. ...
Travere Therapeutics, Inc. (TVTX) Q1 2024 Earnings Call Transcript